久久精品国产亚洲精品-久久精品国产亚洲精品2025-久久精品国产亚洲蜜臀av大全-久久精品国产亚洲欧美-久久精品国产亚洲七七-久久精品国产亚洲夜色aⅴ网站

C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on targeting the science of protein degradation to create a new generation of drugs that will change patients' lives. C4T is using its TORPEDO? platform to effectively design and optimize small molecule drugs that use the body's natural protein recycling system to rapidly degrade disease-causing proteins, potentially overcoming drug resistance. C4T is advancing multiple targeted oncology programs to the clinical stage and expanding its research platform to deliver more drugs for hard-to-treat diseases.

On May 30, 2023, Betta Pharmaceuticals entered into a collaboration with C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC). Betta Pharmaceuticals acquired the right to develop, manufacture and commercialize CFT8919 in China (including Hong Kong, Macau and Taiwan) and to receive an agreed percentage of sales commission outside the aforementioned regions.

InventisBio, founded by U.S. returned Ph.D.s at Shanghai Zhangjiang HiTech Park in 2013, is a rapidly growing biotech company focusing on the development of innovative medicines targeting on tumor and metabolic diseases. The company currently has 4 candidate drugs targeting tumor and gout. Except for D-0316, there are 2 other candidates under phase I clinical trials in China and the U.S.. Furthermore, InventisBio also focuses on the drug development to combine with other immunotherapies.

On December 28^th, 2018, Betta Pharma reached a strategic collaboration agreement with InventsBio Inc. on the development and commercialization of D-0316 in China (including mainland, Hongkong and Taiwan).

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies, and proprietary cancer vaccine platforms. Agenus has more than 26 years of experience in the development of immuno-oncology therapies and has entered into equity investments agreements as well as licensing agreements with several multinational pharmaceutical companies. The U.S. biopharmaceutical companies Incyte Corporation (NASDAQ: INCY) and Gilead Sciences, Inc. (NASDAQ: GILD) are both stockholders of Agenus and are also key collaborators of Agenus.

On June 22, 2020, Betta Pharmaceuticals Co., Ltd. announced that it has entered into an agreement with Agenus Inc. that Betta has obtained an exclusive right to develop and commercialize Balstilimab (a PD-1 mAb) and Zalifrelimab (a CTLA-4 mAb) in all uses (excluding intravesical delivery), as a monotherapy or combination therapy with other components in Greater China (including Hong Kong, Macao and Taiwan). In the meantime, Betta shall purchase Agenus’ newly-issued shares, to strength the collaboration of both parties.

Mabworks is a national high-tech enterprise founded by a team of overseas returnees focusing on the antibody design and research, clinical development and commercialization. Mabworks has a leading antibody discovery and development platform. Its MIL60 program, currently in the stage of clinical study, is targeting vascular endothelial growth factor (VEGF), and is being developed for 7 solid tumor indications including non-small cell lung cancer, colorectal cancer and breast cancer.

On February 28^th, 2017, Betta Pharma reached an agreement with Beijing Mabworks to collaborate on the MIL60 program, expanding Betta Pharma’s biologics pipeline.

Located in Florida, U.S., Xcovery is a biopharmaceutical company focusing on the discovery and development of innovative medicines for advanced tumor treatment and improvement of cancer patient care. Xcovery has built up an oncology pipeline that targets multiple malignant diseases. The leading product, ensartinib hydrochloride (X-396), is a small molecule ALK inhibitor to treat ALK+ NSCLC patients.

On October 25^th, 2014, Betta Pharma invested 20 million US dollars in Xcovery to jointly develop a next-generation ALK inhibitor X-396 (ensartinib hydrochloride).

On July 26^th, 2017, Betta Pharma increased the holdings of Xcovery and became its controlling shareholder. Betta Pharma and Xcovery are jointly advancing the global clinical development of X-396 (ensartinib hydrochloride).

Located in Shanghai, Anew Pharma is an innovative pharmaceutical company founded by overseas returnees, focusing on the development of the targeted therapy CM082. With the innovative business model and booming CRO clusters in China, Anew Pharma integrates various sources and applying them on innovative drug development.

On February 26^th, 2017, Betta Pharma invested 370 million RMB to acquire 77.4% of Anew Pharmaecuticals Co., Ltd., and took over the development of vorolanib (CM082).

On June 16^th, 2017, Betta Pharma acquired Anew Pharma, and owned the China right of vorolanib.

Tyrogenex is a U.S. biotech company dedicated to discover and develop multi-kinase inhibitors targeting angiogenesis to treat solid tumor indications. Tyrogenex discovered a novel antitumor small molecule compound, which is a dual-target inhibitor of vascular endothelial growth factor receptor (VEGFR) and human platelet-derived growth factor receptor (PDGFR).

On August 25^th, 2017, Betta Pharma signed an agreement with Tyrogenex Inc. in Washington D.C. to co-develop the oncology indications of vorolanib in ex-China regions.

Merus focuses on the clinical development of tumor immunotherapeutics, and has established the Biclonics^? platform to develop innovative human bispecific antibodies. Based on the immunoglobulin IgG, the Biclonics^? platform produces bispecific antibodies that have met industry standards. Through pre-clinical and clinical studies, the antibodies produced by this platform were found to share similar characteristics with conventional monoclonal antibodies, such as long half-life and low immunogenicity.

On December 11^th, 2018, Betta Pharma reached a strategic collaboration agreement with Merus and obtained the exclusive right to develop and commercialize MCLA-129 in China.

The mission of Repugene is to integrate precision medicine into public healthcare, developing gene sequencing technology and products. The services provided by Repugene include regular health checkup, oncogene screening and detection, research collaboration, data processing and cloud computing, artificial intelligence, immunotherapy, companion diagnostics for pharmaceutical research and development, bioinformatics analysis and etc.. Driven by its scientific collaboration, technology innovation and product development, Repugene strives for providing better clinical solutions to patients and healthcare institutes, promoting the development of the precision medicine industry.

On February 26^th, Betta Pharma signed a strategic collaboration agreement with Repugene, strengthening their collaboration on precision medicine.

Meryx focuses on the discovery and development of small molecule immuno-oncology therapeutics, dedicating its R&D efforts to the development of kinase inhibitors targeting Mer, to treat hematologic and solid tumor indications.

On Juy 17^th, 2017, Betta Pharma reached a strategic collaboration agreement with Meryx and obtained the exclusive right to develop and commercialize MRX-2843 in China (including mainland China, Hong Kong, Taiwan and Macau).

Beijing Biostar Biotechnologies, Ltd. was established in Haidian Park, Zhongguancun Science and Technology Zone, Beijing in July 2002. It is a national high-tech enterprise led by a team of U.S. returnees, focusing on the discovery, technology transfer and consultation of anticancer small molecule drugs. Its leading product UTD1 is a national first-class oncology innovative drug, and it is also the first new epothilone-based anticancer drug approved for clinical trials in China, indicating Biostar’s advanced R&D capabilities.

In May, 2017, Betta Pharma invested in Beijing Biostar Technologies, Ltd.

Hangzhou DAC Biotech is a Chinese biotech company jointly founded by U.S. returnees-comprised entrepreneurs’ team, Zhejiang pharmaceutical enterprises and venture capital firms in Yuhang, Hangzhou, 2012. The core team is built up with 5 Ph.D. returnees and 36 Ph.D. and M.A. recruited in China. Hangzhou DAC Biotech focuses on developing and commercializing antibody-conjugated drugs for targeted cancer treatments.

In December, 2015, Betta Pharma invested in Hangzhou DAC Biotech.

Based in Binjiang, Hangzhou, HanX Biopharmaceuticals is an innovative biopharmaceutical company with a senior executive team comprised of overseas returnees and industry veterans, focusing on the research and development of innovative antibody therapeutics. As of now, HanX has set up the development and commercialization platforms adhering to global standards, and developed a pipeline targeting tumor, autoimmune disease, inflammation and cardiovascular disease.

In January, 2017, Betta Pharma invested in HanX Biopharmaceuticals.

Amgen is focusing on the discovery, development, manufacturing and sales of innovative drugs, and it is devoted to benefit patients with unmet medical needs. Since its establishment in 1980, Amgen has become one of the global leading biotech companies providing innovative drugs for millions of patients in more than 100 countries and regions. The strong pipeline and the global-leading production level of Amgen ensure its quality supply as well as its leadership in biologics production. Through its scientists’ research on key disease metabolisms, Amgen develops multiple leading innovative biotherapeutics and establishes itself as a leader in the global biotechnology field.

On May 10^th, 2013, Betta Pharma signed a collaboration contract with Amgen to promote the Vectibix in China.

Equinox Science LLC is a joint venture founded by Betta Pharma and Tyrogenex in Newcastle, DE, U.S. in 2017, focusing on the co-development of vorolanib (X-82) for cancer treatments. As of now, Equinox Sciences owns the global rights of vorolanib (X-82) in oncology and ophthalmology indications except for China, and the business scope includes the development, manufacturing, commercialization and marketing of vorolanib.

In January, 2017, Betta Pharma established Equinox Sciences LLC in joint venture with Tyrogenex.